Which medications are contraindicated with fluoxetine?

Absolute Contraindications with Fluoxetine

Fluoxetine is absolutely contraindicated with MAOIs (monoamine oxidase inhibitors), thioridazine, and pimozide due to life-threatening risks including serotonin syndrome, serious ventricular arrhythmias, and sudden death. 1

Medications That Are Absolutely Contraindicated

MAOIs (Monoamine Oxidase Inhibitors)

• Do not combine fluoxetine with MAOIs - this combination causes severe serotonin syndrome characterized by mental status changes (hypomania, confusion), myoclonus, hypertension, tremor, and diarrhea 2
• Critical washout period: Wait at least 5 weeks after stopping fluoxetine before starting an MAOI due to fluoxetine's exceptionally long half-life 1
• Conversely, wait at least 2 weeks after stopping an MAOI before starting fluoxetine
• The high incidence of adverse effects with this combination has been well-documented, with most patients experiencing the serotonergic syndrome 2

Thioridazine

• Absolute contraindication due to risk of serious ventricular arrhythmias and sudden death from elevated thioridazine plasma levels 1
• Must wait minimum 5 weeks after discontinuing fluoxetine before starting thioridazine
• Fluoxetine's potent CYP2D6 inhibition dramatically increases thioridazine levels

Pimozide

• Concomitant use is contraindicated due to risk of QTc prolongation and drug interactions 1
• Clinical studies demonstrate increased risk when pimozide is combined with antidepressants

Medications Requiring Extreme Caution (High-Risk Interactions)

Drugs Metabolized by CYP2D6 with Narrow Therapeutic Index

Fluoxetine is a potent CYP2D6 inhibitor that converts normal metabolizers into poor metabolizers 3. This is particularly dangerous with:

• Antiarrhythmics: Flecainide, propafenone - risk of serious cardiac arrhythmias 1
• Tricyclic antidepressants (TCAs): Risk of toxic levels; start at low end of dose range 1
• Vinblastine: Narrow therapeutic index chemotherapy agent 1

Clinical pearl: Fluoxetine at 20 mg/day converts approximately 43% of extensive metabolizers to poor metabolizers, and this effect persists for 5 weeks after discontinuation due to its long half-life 3

Other Antipsychotics

• Haloperidol and clozapine: Elevated blood levels observed with concurrent fluoxetine 1
• Monitor closely for extrapyramidal symptoms and toxicity

Serotonergic Agents (Serotonin Syndrome Risk)

• Triptans (sumatriptan, etc.): Risk of serotonin syndrome, though some data suggests relative safety with careful monitoring 1, 4
• Tramadol: Increased serotonin syndrome risk 1
• Tryptophan: Five patients experienced agitation, restlessness, and GI distress 1
• Lithium: Cases of both increased/decreased lithium levels and serotonin syndrome reported; monitor lithium levels closely 1

Anticoagulants and Antiplatelet Agents

• Warfarin, NSAIDs, aspirin: Increased bleeding risk due to serotonin reuptake inhibition affecting platelet function 1
• Use caution and monitor for bleeding

Anticonvulsants

• Phenytoin and carbamazepine: Elevated anticonvulsant concentrations and clinical toxicity reported 1
• Monitor drug levels and adjust doses accordingly

Benzodiazepines

• Diazepam: Prolonged half-life 1
• Alprazolam: Increased plasma concentrations and psychomotor performance impairment 1

Critical Pharmacogenetic Considerations

FDA safety labeling mandates caution in patients with:

• CYP2D6 poor metabolizer status
• Congenital long QT syndrome
• Family history of long QT syndrome or sudden cardiac death
• Conditions predisposing to QT prolongation 3

Fatal cases have been documented in CYP2D6 poor metabolizers, including a 9-year-old child on high-dose fluoxetine who experienced seizures, status epilepticus, cardiac arrest, and death 3. The combination of genetic poor metabolizer status plus fluoxetine's auto-inhibition of CYP2D6 creates particularly dangerous drug accumulation.

Key Clinical Pitfalls to Avoid

1. The 5-week rule: Always remember fluoxetine's active metabolite norfluoxetine has an extremely long half-life - drug interactions persist for 5 weeks after discontinuation 1

2. Dose-dependent toxicity: Higher fluoxetine doses (especially >20 mg/day) dramatically increase the risk of converting patients to poor metabolizer phenotype 3

3. Don't ignore genetic testing: In patients requiring narrow therapeutic index drugs metabolized by CYP2D6, consider pharmacogenetic testing before initiating fluoxetine 3

4. Start low with combination therapy: When adding fluoxetine to existing medications metabolized by CYP2D6, reduce the dose of the original medication 1